Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Undifferentiated Ovarian Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Undifferentiated Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2B
Pembrolizumab
Roswell Park Cancer Institute
Phase 2B
Letrozole
Mayo Clinic
Phase 2B
Epirubicin
Roswell Park Cancer Institute
Phase 2B
Urokinase-Derived Peptide A6
Gynecologic Oncology Group
Phase 2B

View all 12 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →